A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for men at increased risk of developing prostate cancer, the second-leading cause of cancer deaths in U.S. men.
This article was originally published on MedicalXpress.com

